Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 200.1 Million EUR | -6.5% |
| 2022 | 214 Million USD | 73.52% |
| 2021 | 123.32 Million EUR | -7.19% |
| 2020 | 132.87 Million EUR | 1083.76% |
| 2019 | 11.22 Million EUR | -92.59% |
| 2018 | 151.5 Million EUR | 0.07% |
| 2017 | 151.4 Million EUR | -0.79% |
| 2016 | 152.6 Million EUR | -25.2% |
| 2015 | 204 Million EUR | -12.97% |
| 2014 | 234.4 Million EUR | -9.08% |
| 2013 | 257.8 Million EUR | 88.73% |
| 2012 | 136.6 Million EUR | 54.0% |
| 2011 | 88.7 Million EUR | -19.36% |
| 2010 | 110 Million EUR | -16.29% |
| 2009 | 131.4 Million EUR | -10.18% |
| 2008 | 146.3 Million EUR | 3468.29% |
| 2007 | 4.1 Million EUR | -58.16% |
| 2006 | 9.8 Million EUR | -82.53% |
| 2005 | 56.1 Million EUR | -53.52% |
| 2004 | 120.7 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 285.92 Million EUR | -2.62% |
| 2024 Q2 | 263.7 Million EUR | 35.51% |
| 2024 Q1 | 209.97 Million EUR | -2.7% |
| 2023 Q3 | 211.84 Million USD | -6.08% |
| 2023 Q2 | 225.56 Million USD | -1.18% |
| 2023 Q1 | 228.25 Million USD | -0.3% |
| 2023 Q4 | 220.85 Million EUR | 4.26% |
| 2023 FY | 200.1 Million EUR | -6.5% |
| 2022 Q4 | 228.92 Million USD | 8.65% |
| 2022 FY | 214 Million USD | 73.52% |
| 2022 Q1 | 131.9 Million EUR | 21.57% |
| 2022 Q2 | 265.77 Million EUR | 101.5% |
| 2022 Q3 | 210.7 Million EUR | -20.72% |
| 2021 Q2 | 127.84 Million EUR | 0.81% |
| 2021 Q4 | 108.5 Million EUR | 0.46% |
| 2021 Q3 | 108 Million EUR | -15.52% |
| 2021 Q1 | 126.81 Million EUR | 16.77% |
| 2021 FY | 123.32 Million EUR | -7.19% |
| 2020 Q1 | 158.9 Million EUR | 1489.0% |
| 2020 FY | 132.87 Million EUR | 1083.76% |
| 2020 Q2 | 159.2 Million EUR | 0.19% |
| 2020 Q3 | 108.4 Million EUR | -31.91% |
| 2020 Q4 | 108.6 Million EUR | 0.18% |
| 2019 FY | 11.22 Million EUR | -92.59% |
| 2019 Q4 | 10 Million EUR | 21.95% |
| 2019 Q2 | 38 Million EUR | -75.99% |
| 2019 Q3 | 8.2 Million EUR | -78.42% |
| 2019 Q1 | 158.3 Million EUR | 4.49% |
| 2018 Q1 | 190.1 Million EUR | 25.56% |
| 2018 FY | 151.5 Million EUR | 0.07% |
| 2018 Q4 | 151.5 Million EUR | 0.0% |
| 2018 Q3 | 151.5 Million EUR | 0.07% |
| 2018 Q2 | 151.4 Million EUR | -20.36% |
| 2017 Q1 | 152.4 Million EUR | -0.13% |
| 2017 FY | 151.4 Million EUR | -0.79% |
| 2017 Q4 | 151.4 Million EUR | 0.0% |
| 2017 Q3 | 151.4 Million EUR | 0.0% |
| 2017 Q2 | 151.4 Million EUR | -0.66% |
| 2016 Q1 | 185.9 Million EUR | -1.01% |
| 2016 FY | 152.6 Million EUR | -25.2% |
| 2016 Q4 | 152.6 Million EUR | -11.94% |
| 2016 Q3 | 173.3 Million EUR | -7.18% |
| 2016 Q2 | 186.7 Million EUR | 0.43% |
| 2015 Q3 | 219.7 Million EUR | -4.27% |
| 2015 FY | 204 Million EUR | -12.97% |
| 2015 Q4 | 187.8 Million EUR | -14.52% |
| 2015 Q2 | 229.5 Million EUR | -0.52% |
| 2015 Q1 | 230.7 Million EUR | -1.58% |
| 2014 Q2 | 252.8 Million EUR | -0.47% |
| 2014 Q3 | 242.9 Million EUR | -3.92% |
| 2014 Q4 | 234.4 Million EUR | -3.5% |
| 2014 FY | 234.4 Million EUR | -9.08% |
| 2014 Q1 | 254 Million EUR | -1.47% |
| 2013 Q2 | 278.2 Million EUR | 58.88% |
| 2013 Q1 | 175.1 Million EUR | 28.18% |
| 2013 FY | 257.8 Million EUR | 88.73% |
| 2013 Q4 | 257.8 Million EUR | -4.84% |
| 2013 Q3 | 270.9 Million EUR | -2.62% |
| 2012 Q3 | 149.9 Million EUR | -4.83% |
| 2012 Q2 | 157.5 Million EUR | -3.73% |
| 2012 Q1 | 163.6 Million EUR | 84.44% |
| 2012 FY | 136.6 Million EUR | 54.0% |
| 2012 Q4 | 136.6 Million EUR | -8.87% |
| 2011 Q2 | 105.7 Million EUR | -4.0% |
| 2011 Q3 | 99.9 Million EUR | -5.49% |
| 2011 Q4 | 88.7 Million EUR | -11.21% |
| 2011 Q1 | 110.1 Million EUR | 0.09% |
| 2011 FY | 88.7 Million EUR | -19.36% |
| 2010 FY | 110 Million EUR | -16.29% |
| 2010 Q3 | 121.3 Million EUR | -4.41% |
| 2010 Q4 | 110 Million EUR | -9.32% |
| 2010 Q1 | 131.6 Million EUR | 0.15% |
| 2010 Q2 | 126.9 Million EUR | -3.57% |
| 2009 FY | 131.4 Million EUR | -10.18% |
| 2009 Q4 | 131.4 Million EUR | 0.0% |
| 2008 FY | 146.3 Million EUR | 3468.29% |
| 2007 FY | 4.1 Million EUR | -58.16% |
| 2006 Q4 | 9.8 Million EUR | 0.0% |
| 2006 FY | 9.8 Million EUR | -82.53% |
| 2005 FY | 56.1 Million EUR | -53.52% |
| 2004 FY | 120.7 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | 99.3% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 99.517% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -100.811% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -373.397% |
| Novartis AG | 26.34 Billion USD | 99.241% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -395.226% |